"Our Smiles" Program
|
Join Our Mailing List
Receive the latest JKF news and event updates.
Email Address:
|
Our Mission
The Joshua Kahan Fund is fighting to cure pediatric leukemia and improve the quality of life for pediatric cancer patients and their families. It raises funds to advance carefully selected, scientific research projects, while perpetuating Josh's name and memory through all of its actions.
"Over the past 5 years, The Joshua Kahan Fund has become the fastest growing philanthropic organization dedicated to advancing the mission of the Division of Oncology at The Children's Hospital of Philadelphia"
Gerrett M Brodeur, MD
The Division of Oncology Children's Hospital of Philadelphia
|
|
JKF Headlines
|
In 2007, we made our largest donation since the inception of our Fund. We committed to donate $1,000,000 to The Children’s Hospital of Philadelphia to create something that has never been done before; an endowed Research Chair solely dedicated to finding a cure for pediatric leukemia. Our donation was deemed so important that Children’s Hospital themselves agreed to donate an additional $1,000,000. This $2,000,000 endowment is unprecedented. Once completed The Joshua Kahan Pediatric Leukemia Research Chair will have continual funding to support high quality, state of the art research objectives at one of the best children’s hospital in world. It is our belief that funding like this will give doctors and scientists more tools than ever before and will undoubtedly help us find a cure for pediatric leukemia. |
|
Action news story on 1 million dollar donation presented at 10th Anniversary Dinner Dance for Joshua Kahan Pediatric Leukemia Research Chair. |
|
News Story from The Early Show the 2nd Annual Prom at the Children's Hospital of Philadelphia |
Learn about the Fund and How You Can Help
 |
You can join us in our effort to fight to cure pediatric leukemia by making a contribution of $25, $50, $100 or whatever you can afford to support our work at The Joshua Kahan Fund.
Donations can be made directly, in honor of someone special, or in memory of a loved one or friend. A special card will be sent in recognition of your gift.
Please fill out the appropriate information. If you need help, please contact us for assistance.
The Joshua Kahan Fund, Inc. is a New Jersey nonprofit corporation. The Fund is a public charity exempt from federal income tax under Section 501 (c)(3) of the Internal Revenue Code.
|
|
|
Leukemia News
-
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research.
-
Researchers have discovered a key reason why chronic myeloid leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study indicates that CML progresses when immature white blood cells lose a molecule called miR-328 and this traps the cells in a rapidly growing, immature state. The research should provide a better understanding of the blast-crisis stage of CML, and it suggests a possible new treatment strategy for the disease.
-
Scientists studying acute forms of leukemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
-
Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets. Now, researchers have found a gene regulator they believe to be a key player in DS-AMKL, advancing understanding of how the disease develops and how to treat it.
Events
Sponsors
Send a Smile
|